[1]Patent:WO2007/60404,2007,A1.Locationinpatent:Page/Pagecolumn61-62
[1]Pike,KurtG.;Malagu,Karine;Hummersone,MarcG.;Menear,KeithA.;Duggan,HeatherM.E.;Gomez,Sylvie;Martin,NiallM.B.;Ruston,Linette;Pass,SarahL.;Pass,Martin[BioorganicandMedicinalChemistryLetters,2013,vol.23,#5,p.1212-1216]
[2]CurrentPatentAssignee:ASTRAZENECAPLC-WO2007/60404,2007,A1Locationinpatent:Page/Pagecolumn88-89
[1]Pike,KurtG.;Malagu,Karine;Hummersone,MarcG.;Menear,KeithA.;Duggan,HeatherM.E.;Gomez,Sylvie;Martin,NiallM.B.;Ruston,Linette;Pass,SarahL.;Pass,Martin[BioorganicandMedicinalChemistryLetters,2013,vol.23,#5,p.1212-1216]
[1]BioorganicandMedicinalChemistryLetters,2013,vol.23,p.1212-1216
[1]BioorganicandMedicinalChemistryLetters,2013,vol.23,p.1212-1216
Title: Identification of potent Yes1 kinase inhibitors using a library screening approach.
Journal: Bioorganic & medicinal chemistry letters 20130801
Title: Optimization of potent and selective dual mTORC1 and mTORC2 inhibitors: the discovery of AZD8055 and AZD2014.
Journal: Bioorganic & medicinal chemistry letters 20130301
Title: Harnessing the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia: eliminating activity by targeting at different levels.
Journal: Oncotarget 20120801
Title: Threonine-120 phosphorylation regulated by phosphoinositide-3-kinase/Akt and mammalian target of rapamycin pathway signaling limits the antitumor activity of mammalian sterile 20-like kinase 1.
Journal: The Journal of biological chemistry 20120706
Title: Inhibition of mTORC1 kinase activates Smads 1 and 5 but not Smad8 in human prostate cancer cells, mediating cytostatic response to rapamycin.
Journal: Molecular cancer research : MCR 20120601
Title: The synergistic interaction of MEK and PI3K inhibitors is modulated by mTOR inhibition.
Journal: British journal of cancer 20120410
Title: Quantitative visualization of autophagy induction by mTOR inhibitors.
Journal: Methods in molecular biology (Clifton, N.J.) 20120101
Title: Inhibition of PI3K-Akt-mTOR signaling in glioblastoma by mTORC1/2 inhibitors.
Journal: Methods in molecular biology (Clifton, N.J.) 20120101
Title: Mechanical regulation of glycogen synthase kinase 3β (GSK3β) in mesenchymal stem cells is dependent on Akt protein serine 473 phosphorylation via mTORC2 protein.
Journal: The Journal of biological chemistry 20111111
Title: The inhibition of MAPK potentiates the anti-angiogenic efficacy of mTOR inhibitors.
Journal: Biochemical and biophysical research communications 20110422
Title: Discovery of 9-(6-aminopyridin-3-yl)-1-(3-(trifluoromethyl)phenyl)benzo[h][1,6]naphthyridin-2(1H)-one (Torin2) as a potent, selective, and orally available mammalian target of rapamycin (mTOR) inhibitor for treatment of cancer.
Journal: Journal of medicinal chemistry 20110310
Title: The discovery and optimisation of pyrido[2,3-d]pyrimidine-2,4-diamines as potent and selective inhibitors of mTOR kinase.
Journal: Bioorganic & medicinal chemistry letters 20091015
Title: Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR).
Journal: The Biochemical journal 20090701
Title: Garcia-Martinez et al. Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR). Biochem.J. (2009)421 29.
Title: Collak FK, et al. Threonine-120 phosphorylation regulated by phosphoinositide-3-kinase/Akt and mammalian target of rapamycin pathway signaling limits the antitumor activity of mammalian sterile 20-like kinase 1.J Biol Chem. 2012 Jul 6;287(28):23698-709. E
Title: Haagensen EJ, et al. The synergistic interaction of MEK and PI3K inhibitors is modulated by mTOR inhibition. Br J Cancer. 2012 Apr 10;106(8):1386-94.
